FDA orders aspiration warning for GLP-1 labels; Mounjaro update approved Nov. 1
Mounjaro's prescribing information now carries an FDA-required warning that GLP-1 receptor agonist drugs can cause pulmonary aspiration during general anesthesia or deep sedation.
Mounjaro's prescribing information now warns about pulmonary aspiration during general anesthesia or deep sedation, a labeling change the FDA required the drug's maker to make. In a September 6, 2024, letter, the agency told Eli Lilly and Company that glucagon-like peptide-1 receptor agonist (GLP-1 RA) medicines as a class need this safety information, and the Mounjaro (tirzepatide) injection label revisions that followed were approved November 1, 2024 [1].
The agency used a mechanism called Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act, which is how the FDA formally notifies a manufacturer that it has identified new safety information belonging in a product's labeling [1]. The letter describes that information as covering "the serious risk of pulmonary aspiration for patients undergoing elective surgeries or procedures requiring general anesthesia or deep sedation" [1].
Supplement S-022 is the piece of Lilly's application that carries out the September 6 notice. According to the approval letter, it provides for Mounjaro labeling revisions matching that letter plus email correspondence with the FDA dated October 11 and October 16, 2024 [1]. The supplements cited in the letter were submitted December 8, 2023, and April 19 and October 3, 2024 [1].
The November 1 action also cleared two unrelated Mounjaro label updates. S-010 changes the Prescribing Information on severe gastrointestinal adverse reactions, adds dysgeusia to Section 6.1 on clinical trials experience, and revises the product description in Sections 11 and 12 [1]. S-015 adds dysesthesia to Section 6.1 [1]. The letter states the application was approved for use as recommended in agreed-upon labeling, and the enclosures listed are the Prescribing Information, Medication Guide, two Instructions for Use documents covering the vial and the single-dose pen, and a Quick Reference Guide [1].
The signature page shows the letter was signed electronically by Monika Houstoun, Pharm.D., M.P.H., deputy director for safety in the FDA's division of diabetes, lipid disorders, and obesity [1]. It was addressed to Linda S. Kelly, Lilly's director of global regulatory affairs for North America [1].
Several deadlines came with the approval. Lilly has 14 days from the letter to file the labeling content in structured product labeling format through the FDA's automated system, and within the same window to update any pending supplements containing labeling changes for this application in Microsoft Word, both marked-up and clean [1]. The company has 7 days to file a statement of intent to comply with rules on promotional materials that mention the product [1]. Patent information on Form FDA 3542 is due within 30 days [1].
The document does not quote the new warning language, say how many aspiration cases or reports prompted the class-wide notice, or describe what labels for other GLP-1 medicines now say [1]. Those details have not been disclosed in the letter.
Why it matters for patients
Pulmonary aspiration happens when stomach contents get into the airway, and the FDA has treated it as a serious risk for this drug class [1]. What changed on paper is that the risk is written into Mounjaro's official prescribing information, the reference clinicians and pharmacists use, rather than being left to individual surgery and anesthesia teams to manage [1]. The letter's audience was the GLP-1 RA group as a whole, so other manufacturers' labels may be affected too, but nothing in this document describes changes to any product besides Mounjaro [1]. The letter gives no instruction to stop or pause the drug before a procedure; no such guidance appears in it.
What happens next
The approval letter was signed November 1, 2024 [1]. Counting from that date, the labeling submission is due within 14 days, the promotional-material statement within 7 days, and the patent form within 30 days [1]. Once filed, FDA says the structured labeling will be accessible through publicly available labeling repositories [1]. The letter does not give a date by which the revised Mounjaro Prescribing Information and Medication Guide will appear there.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.